Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next stepOtte, A., van de Wiele, C. & Dierckx, R. A., Jan-2009, In : Nuclear Medicine Communications. 30, 1, p. 5-15 11 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Radiolabeled immunotherapy (RIT) is becoming a significant step forward in the treatment management of non-Hodgkin's lymphoma (NHL). In this state-of-the-art review article, general details, practical and health economic aspects, and next steps of RIT in NHL are reviewed from the existing literature and latest abstracts. As Y-90-ibritumomab tiuxetan is the only marketed RIT in NHL in Europe, the special focus of this review is on 90Y-ibritumomab tiuxetan, although the whole spectrum of available RIT concepts is highlighted. There is strong evidence to suggest that RIT is not only a safe and efficacious add-on treatment option in third or second line to chemotherapy, but is also a convincing asset as first-line therapy in various indications of lymphoma. Nucl Med Commun 30:5-15 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
|Number of pages||11|
|Journal||Nuclear Medicine Communications|
|Publication status||Published - Jan-2009|
- chemotherapy, I-131-labeled tositumomab (Bexxar), non-Hodgkin's lymphoma, radiolabeled immunotherapy, Y-90-ibritumomab tiuxetan (Zevalin), IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY, B-CELL LYMPHOMA, ALPHA-EMITTING RADIOIMMUNOCONJUGATE, RADIATION SAFETY CONSIDERATIONS, ANTI-CD22 MONOCLONAL-ANTIBODY, RANDOMIZED CONTROLLED TRIAL, NERVOUS-SYSTEM LYMPHOMA, MALIGNANT-LYMPHOMA, LOW-GRADE, MULTICENTER TRIAL